Table 2.
Intravenously and topically delivered iPSCs did not formed teratomas. IV: intravenous.
| iPSC type | Recipient animal | Route of administration | Dose | Frequency of administration | Matrigel | Disease model | Time of observation | Number of animals |
Rate of teratoma formation |
|---|---|---|---|---|---|---|---|---|---|
| C57BL/6-1 | Male, C57BL/6 | IV | 2.5×108/kg | Single | No, but in 200 μL PBS | None | 180 days | 20 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 2.5×108/kg | Single | No, but in 200 μL PBS | None | 18 months | 20 | 0% |
| C57BL/6-1 | Female, C57BL/6 | IV | 2.5×108/kg | Single | No, but in 200 μL PBS | None | 180 days | 20 | 0% |
| C57BL/6-2 | Male, C57BL/6 | IV | 2.5×108/kg | Single | No, but in 200 μL PBS | None | 180 days | 20 | 0% |
| Healthy human iPSC-1 |
SCID-NOD | IV | 2.5×108/kg | Single | No, but in 200 μL PBS | None | 180 days | 20 | 0% |
| Healthy human iPSC-1 |
SCID-NOD | IV | 2.5×108/kg | Single | No, but in 200 μL PBS | None | 18 months | 10 | 0% |
| C57BL/6-2 | Male, C57BL/6 | IV | 2.5×108/kg | Single | No, but in 200 μL PBS | Lung injury caused by intratracheally administered LPS | 180 days | 20 | 0% |
| C57BL/6-2 | Male, C57BL/6 | IV | 5×106/kg | Single | No, but in 200 μL PBS | Paraquat intoxication (lung) | 180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 5×106/kg | Single | No, but in 200 μL PBS | Carbon tetrachloride-induced liver injury | 180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 5×106/kg | Single | No, but in 200 μL PBS | Kidney ischemia-reperfusion injury |
180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 5×106/kg | Single | No, but in 200 μL PBS | Stroke, brain middle artery ischemia-reperfusion injury |
180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 5×106/kg | Single | No, but in 200 μL PBS | Femoral artery wire injury | 180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 5×106/kg | Single | No, but in 200 μL PBS | Hind limb ischemia-reperfusion injury | 180 days | 30 | 0% |
| C57BL/6-2 | Male, C57BL/6 | IV | 5×106/kg | Single | No, but in 200 μL PBS | Streptozotocin-induced insulitis and diabetes | 180 days | 10 | 0% |
| C57BL/6-2 | Male, C57BL/6 | IV | 5×106/kg | 3 times (once daily for 3 days) | No, but in 200 μL PBS | Streptozotocin-induced insulitis and diabetes | 180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 5×106/kg | Single | No, but in 200 μL PBS | Atherosclerosis | 180 days | 10 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 5×106/kg | 20 times (once every 3 days for 60 days) | No, but in 200 μL PBS | Atherosclerosis | 180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 5×106/kg | Single | No, but in 200 μL PBS | Burned skin wound | 180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 2.5×108/kg | Single | No, but in 200 μL PBS | Burned skin wound | 180 days | 10 | 0% |
| C57BL/6-1 | Male, C57BL/6 | IV | 5×106/kg | Single | No, but in 200 μL PBS | Excisional skin wound | 180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | Topically smeared on wound surface | 1×105 | Single | No, but in 15 μL PBS | Excisional skin wound | 180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | Topically smeared on wound surface | 1×105 | Single | No, but in 15μL PBS | Excisional skin wound in streptozotocin-induced insulitis and diabetic mice | 180 days | 30 | 0% |
| C57BL/6-1 | Male, C57BL/6 | Topically smeared on pancreas | 1×106 | Single | No, but in 200 μL low melting point agarose | Streptozotocin-induced insulitis and diabetes | 180 days | 30 | 0% |
| Autologous iPSCs from 4 different monkeys | Individualized, monkey from which cells were used for iPSC induction | Topically smeared on wound surface | 1×106 | Single | No, but in 15 μL PBS | Excisional skin wound | 180 days | 4 | 0% |
| iPSCs from 4 different type 2 diabetic patients | Male, SCID-NOD | IV | 2.5×108/kg | Single | No, but in 200 μL PBS | None | 180 days | 4 | 0% |
| Autologous iPSCs from 4 different monkeys | Male, SCID-NOD | IV | 2.5×108/kg | Single | No, but in 200 μL PBS | None | 180 days | 4 | 0% |